Background: Even though mesenchymal stromal cells (MSCs) mitigate lung and distal organ damage in experimental polymicrobial sepsis, mortality remains high. We investigated whether preconditioning with eicosapentaenoic acid (EPA) would potentiate MSC actions in experimental sepsis by further decreasing lung and distal organ injury, thereby improving survival.
Background
Sepsis remains a major cause of morbidity and mortality worldwide, despite improvements in early diagnosis, antibiotic therapy, and clinical management. Several pharmacotherapeutic approaches have been tested but failed at improving outcomes in clinical trials, thus leaving an urgently unmet need for this devastating condition [1, 2] .
Mesenchymal stromal cells (MSCs)-isolated from the bone marrow, adipose tissue, and other sources-are now known to induce immunomodulation following systemic administration, either by cell contact-dependent mechanisms or by secretion of paracrine factors, resulting in anti-inflammatory and reparative effects in a wide range of diseases [3] [4] [5] [6] . In preclinical models of sepsis, MSC administration improved survival, but did not restore organ function [7] [8] [9] [10] [11] . Although no safety concerns have been observed in initial clinical trials, very few studies have been conducted in critically ill patients [12] [13] [14] . On the experimental front, recent studies have attempted to condition MSCs prior to administration in order to potentiate their therapeutic actions [6, [15] [16] [17] .
Eicosapentaenoic acid (EPA), an omega-3 polyunsaturated fatty acid, may be an interesting agent for MSC preconditioning, since it has shown to modulate inflammatory and remodeling responses by altering profiling of secreted mediators in several inflammatory diseases [18, 19] . We previously found that EPA-exposed MSCs demonstrated enhanced secretion of antiinflammatory and pro-resolution factors, such as resolvin D 1 , prostaglandin E 2 (PGE 2 ), interleukin (IL)-10, and transforming growth factor (TGF)-β. Additionally, EPAMSCs were more potent than non-exposed MSCs in reducing lung inflammation and remodeling in a preclinical model of allergic asthma [17] . We hypothesized whether preconditioning of adipose tissue-derived (AD)-MSCs with EPA might enhance the therapeutic effects of AD-MSCs and thus mitigate lung and multiple organ injury caused by polymicrobial sepsis.
In this current study, the actions of nonpreconditioned and EPA-preconditioned AD-MSCs were comparatively investigated in a widely utilized murine model of sepsis: cecal ligation and puncture (CLP). Endpoint analyses included survival rate; sepsis severity score; lung mechanics and histology; protein levels of selected mediators in lung tissue; total and differential cell counts in blood; effects on morphological abnormalities in the liver, kidney, heart, spleen, and small bowel; macrophage capacity for phagocytosis; and AD-MSC distribution (by technetium99m tagging).
Methods

Ethics statement
This study was approved by the Animal Care and Use Committee (CEUA:121/18) of the Health Sciences Center, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. All animals received humane care in compliance with the "Principles of Laboratory Animal Care" formulated by the National Society for Medical Research and the US National Academy of Sciences Guide for the Care and Use of Laboratory Animals. Animals were housed in standard laboratory cages (12-h light/dark cycles, temperature 23 ± 1°C), three to a cage, with access to food and water ad libitum.
Animal preparation and experimental protocol
All experimental assessments were performed in blind fashion. A total of 152 C57BL/6 mice (144 females and 8 males, weight 25-30 g, age 8-10 weeks), obtained from the animal care facility of the Laboratory of Pulmonary Investigation, Federal University of Rio de Janeiro, were used: 32 females for lung mechanics, histology, biomarker measurement, and distal organ analysis; 32 females for the analysis of blood cellularity; 40 females for the analysis of clinical score and survival rate; 20 females for the analysis of biodistribution in tissues; 20 females to obtain alveolar macrophages; and 8 males as cell donors. All animals were randomly allocated across two groups: control and sepsis (Additional file 1: Figure S1 ). Experimental sepsis was induced using an established model of cecal ligation and puncture (CLP) surgery, as described elsewhere [20] . Briefly, animals were anesthetized by intraperitoneal (i.p.) injection of ketamine and xylazine (0.25 mg kg −1 and 0.025 mg kg −1 , respectively) and a laparotomy (2-cm incision) was performed. The cecum was carefully isolated to prevent damage and ligated with a 3-0 cotton suture. The ligature was placed below the ileocecal valve to prevent bowel obstruction. The cecum was punctured twice with an 18-gauge needle and the animals left to recover from anesthesia. In the control group (C), a sham surgery was performed, in which the abdominal cavity was opened, and the cecum was isolated, but without ligation and puncture. Postoperative care was similar in both groups, consisting of a subcutaneous injection of tramadol hydrochloride (20 mg g −1 body weight) in 1 mL warm (37°C) normal saline (NaCl 0.9%). Twenty-four hours after surgery, the CLP group was subsequently randomized into three subgroups to receive sterile saline (0.05 mL, SAL), nonpreconditioned AD-MSCs (1 × 10 5 cells per mouse, concentrated in 0.05 mL of sterile saline, AD-MSC), or eicosapentaenoic acid (EPA)-preconditioned AD-MSCs (1 × 10 5 cells per mouse, concentrated in 0.05 mL of sterile saline, AD-MSC-EPA) via the intrajugular vein. Twenty-four hours after therapy, mice were euthanized and data analyzed, except for those mice used to evaluate the survival rate, which were euthanized on day 7.
Adipose tissue MSC isolation, characterization, and preconditioning
Male C57BL/6 mice (weight 20-25 g, age 8-10 weeks) were anesthetized with intravenous ketamine (25 mg/kg) and xylazine (2 mg/kg) and used as cell donors. Adipose tissue was obtained from the epididymal fat pads as described elsewhere [3] . Tissues were collected, rinsed in PBS, transferred to a Petri dish, and cut into small pieces. The dissected pieces were washed with PBS and subsequently digested with type I collagenase (1 mg mL −1 in PBS) for 30-40 min at 37°C. After digestion, fresh medium was added, and the suspension was centrifuged at 400×g for 10 min at room temperature. The pellets were resuspended in DMEM containing 1% antibiotic solution (Invitrogen, CA, USA), 20% FBS, and 15 mM HEPES; seeded in T25 flasks (4 mL per flask); and incubated at 37°C in a humidified atmosphere containing 5% CO 2 . On day 3 of culture, the medium was replaced, and non-adherent cells were removed. Adherent cells reaching 80% confluence were passaged with 0.25% trypsin-EDTA solution (Gibco, NM, USA). Cells from the third passage were characterized on the basis of the following criteria: (1) MSCs must be plastic-adherent when maintained in standard culture conditions using tissue culture flasks and (2) 95% of the MSC population must express specific surface antigens by flow cytometry [3] . ADMSCs were preconditioned or not with EPA (10 μM, CAS 10417-94-4, Cayman Chemical, Ann Arbor, MI) for 6 h. For therapeutic injection, cells were detached with trypsin, washed, and resuspended in sterile saline.
Flow cytometry was performed using commercially available antibodies against CD45 (hematopoietic marker), CD31 (endothelial cell marker), MHC class II, CD29 (β1-integrin), CD49e (integrin alpha-5), and CD44 (hyaluronic acid receptor), all from BD Biosciences (São Paulo, Brazil).
Additionally, cell survival and viability were investigated by using annexin V-FITC and propidium iodide (PI) staining [6] . Briefly, harvested AD-MSCs were resuspended in 1× binding buffer containing annexin V-FITC (Calbiochem, Billerica, MA). After incubation for 15 min at room temperature, cell suspension was diluted with 1× binding buffer and incubated with PI. After 15 min at room temperature, cells were subjected to flow cytometry acquisition. All data were acquired in a FACSCalibur flow cytometer (BD Biosciences Immunocytometry Systems, San Jose, CA) and analyzed using Flow Jo X 10.0.7 software (Tree Star Inc., Ashland, OR).
To collect extracellular vesicles (EVs), the cells were cultured with serum-free medium for 48 h. The medium was collected and centrifuged at 2000×g for 20 min at 4°C to remove cellular debris, followed by two rounds of ultracentrifugation (100,000×g) for 1 h each at 4°C. The precipitate was collected and suspended in 0.9% saline solution for immediate use. Following collection of conditioned media for EV isolation, nonpreconditioned or EPA-preconditioned AD-MSCs were fixed in 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.2) for 2 h and washed twice with cacodylate buffer. Immediately thereafter, post-fixation with OsO 4 and FeCNK solution (1:1) was performed for 45 min, followed by dehydration in a graded ethanol series for 10 min at each concentration (30%, 50%, 70%, 90%, 100%, the latter three times). After critical point drying, the coverslips were analyzed and ultrastructural images of EVs being released from AD-MSC surfaces were acquired in a FEI QUANTA 250 scanning electron microscope (FEI, USA). The size distribution and concentration of EVs were evaluated by dynamic light scattering (DLS) using a Zetasizer Nano ZS ZEN3600 (Malvern Instruments, Malvern, UK) equipped with a solidstate He-Ne laser at 633-nm wavelength. The intensity of the scattered light was measured at 173°. All measurements were undertaken in triplicates at 25°C. Data processing and analysis were performed using Zetasizer software version 7.03.
Isolation of alveolar macrophages and phagocytosis capacity
Alveolar macrophages were obtained from the bronchoalveolar lavage fluid (BALF) of C, CLP-SAL, CLP-AD-MSC, and CLP-AD-MSC-EPA mice [17, 21] . Experiments were performed in triplicate. BALF was centrifuged at 300g for 10 min and the cellular pellet was washed with saline, resuspended in red blood cell lysis buffer (8.3 g NH 4 Cl, 1 g KHCO 3 , 1.8 mL 5% EDTA in 1 L distilled water) for 5 min at room temperature, and centrifuged again at 300g for 10 min. The pelleted cells were resuspended and cultured in a 12-well culture plate at 37°C with 5% CO 2 at a concentration of 10 5 cells per well in 1 mL RPMI 1640 medium (Sigma Chemical Co., St. Louis, MO) supplemented with 10% FBS, 1 mM pyruvate, 1% nonessential amino acids, 14 mM glucose, 17.9 mM NaHCO 3 , 10 mM HEPES, 100 U/mL penicillin, and 0.1 mg/mL streptomycin. After 2 h of incubation, nonadherent cells were washed off with saline, and the medium was refreshed. Alveolar macrophages were stimulated with conditioned media obtained from AD-MSCs stimulated or not with EPA for an additional 24 h. Alveolar macrophages were then washed with sterile saline, harvested from the culture plates, and pelleted by centrifugation (600g for 5 min).
The phagocytosis capacity of alveolar macrophages was tested with pHrodo™ Green Zymosan A BioParticles® (Life Technologies, Carlsbad, USA), in accordance with the supplier's instructions. Briefly, alveolar macrophages were plated with nonpreconditioned or EPApreconditioned AD-MSCs on a 96-well tissue culture plate and incubated in RPMI1640 10% FBS with 1% penicillin/streptomycin for 2 h at 37°C, in a 5% CO 2 atmosphere, for cell adherence. Wells were then washed with saline solution, and alveolar macrophages incubated with media containing fluorescently labeled zymosan particles (0.5 mg mL −1 ) for 2 h. Fluorescence was measured in a microplate reader (Perkin-Elmer, Waltham, USA) [18] . Phagocytosis of fluorescently labeled Saccharomyces cerevisiae BioParticles was quantified by measuring intracellular fluorescence emitted by engulfed particles at 585 nm.
Clinical sepsis severity score and survival rate
At 24 h (time therapy started) and 48 h (time of analysis) after CLP surgery, a cohort of mice had their clinical score evaluated. The score consisted of analyzing the following parameters: presence of piloerection, altered respiration rate, fecal alterations, lacrimation/eyelid changes, contraction of the abdomen, lack of strength when grasping, change in body temperature, escape response after touch, exploration of the environment, and compromised locomotor activity. For the presence of each of the aforementioned parameters, one point was computed, while no point was given in the absence of such abnormalities. The score was then added for each mouse and graded as follows: 0, no clinical abnormalities; 1 to 3, mild sepsis; 4 to 7, moderate sepsis; 8 to 10, severe sepsis. All mice had free access to water and food and were monitored for 7 days to evaluate survival rate. During this period, all animals received tramadol hydrochloride (20 mg g −1 body weight) via subcutaneous injection every 6 h for pain management.
Lung mechanics
Twenty-four hours after AD-MSC administration, another set of animals were sedated (diazepam 1 mg kg
intraperitoneally), anesthetized (thiopental sodium 20 mg kg −1 intraperitoneally), tracheotomized, paralyzed (vecuronium bromide, 0.005 mg kg −1 intravenously), and ventilated using a constant-flow ventilator (Samay VR15; Universidad de la Republica, Montevideo, Uruguay) with the following settings: respiratory rate 100 breaths/min, tidal volume (V T ) 0.2 mL, and fraction of inspired oxygen (FIO 2 ) 0.21. The anterior chest wall was surgically removed and a positive endexpiratory pressure (PEEP) of 2 cmH 2 O applied. Airflow and tracheal pressure (Ptr) were measured. Lung mechanics were analyzed by the end-inflation occlusion method [22] . In an open-chest preparation, Ptr reflects transpulmonary pressure (PL). Briefly, after end-inspiratory occlusion, there is an initial rapid decline in PL from the preocclusion value down to an inflection point, followed by a slow pressure decay until a plateau is reached. This plateau corresponds to the elastic recoil pressure of the lung (Pel). Static lung elastance (Est,L) was determined by dividing Pel by V T . Lung mechanics measurements were performed ten times in each animal. All data were analyzed using ANADAT software (RHT-InfoData, Inc., Montreal, Quebec, Canada).
Lung histology
The right lung was fixed in 4% buffered formalin and embedded in paraffin. Sections (4 μm thick) were stained with hematoxylin-eosin. Photomicrographs at magnifications of × 25, × 100, and × 400 were obtained from ten non-overlapping fields of view per section using a light microscope (Olympus BX51, Olympus Latin America Inc., Brazil). Diffuse alveolar damage (DAD) was quantified using a weighted scoring system by two investigators (J.D.S. and V.L.C.) blinded to group assignment. Briefly, scores of 0 to 4 were used to represent alveolar collapse, interstitial edema, and alveolar septal inflammation, with 0 standing for no effect and 4 for maximum severity. Additionally, the extent of each scored characteristic per field of view was determined on a scale of 0 to 4, with 0 standing for no visible evidence and 4 for complete involvement. Scores were calculated as the product of severity and extent of each feature, on a range of 0 to 16. The cumulative DAD score was calculated as the sum of each score characteristic and ranged from 0 to 48. The fraction area of total and differential cell counts in lung tissue was determined by the point-counting technique across ten random, non-overlapping microscopic fields at × 1000 magnification [23] . Collagen fibers (Picrosirius-polarization method) were quantified in alveolar septa at × 400 magnification. The area occupied by fibers was determined by digital densitometric recognition (Image-Pro Plus 7.1 software, Media Cybernetics, Silver Spring, MD, USA) and divided by the area of each septum [24] .
Total and differential cellularity in blood
Blood was collected with a heparinized needle through the abdominal vein. Total leukocyte numbers were measured in a Neubauer chamber under light microscopy after diluting the samples in Türk solution (2% acetic acid). Differential cell counts (monocytes and neutrophils, × 1000 magnification) were performed in Cytospin™ smears stained by the May-Grünwald-Giemsa method under a light microscope (Olympus BX51, Olympus Latin America Inc., Brazil).
Pathologic findings in distal organs
The liver, kidney, heart, spleen, and small bowel were fixed in 4% buffered formalin, embedded in paraffin, and cut into slices 4 μm thick, which were stained with hematoxylin and eosin (Vetec Química Fina, Rio de Janeiro, Brazil). A semiquantitative scoring system based on severity and extension of injury was used to assess the degree of distal organs damage. Severity was graded as follows: 1 = normal tissue, 2 = mild injury, 3 = moderate injury, and 4 = severe injury. Extension of injury was graded as follows: 0 = normal tissue, 1 = damage to 1-25% of total tissue examined, 2 = damage to 26-50% of total tissue examined, 3 = damage to 51-75% of total tissue examined, and 4 = damage to 76-100% of total tissue examined. The final score is obtained by multiplying severity and extension of injury in each examined tissue. These analyses were performed by two expert pathologists (J.D.S. and V.L.C.).
Analysis of multiple soluble factors in vivo and after in vitro stimulation using enzyme-linked immunosorbent assay (ELISA) and automated enzyme immunoassay (EIA)
For protein isolation, the right lobes of the lungs were frozen in liquid nitrogen and stored at − 80°C until analysis. Lung tissue was homogenized in lysis buffer (PBS 1×, Triton X 0.01%, and 1× Roche protease inhibitor cocktail; Roche Diagnostic, Mannheim, Germany) using a glass Potter homogenizer with Teflon piston. Total cytokines were quantified in Isotype controls were used as negative control (light gray histograms). Yaxis: cell count; X-axis: fluorescence intensity. c Note the homogeneous fibroblastoid morphology of adherent AD-MSCs, which is similar in nonpreconditioned (AD-MSC) and EPA-preconditioned AD-MSCs accordance with the manufacturer's protocol and normalized to the total content of protein as quantified by Bradford's reagent (Sigma-Aldrich, St Louis, MO, USA). Protein levels of interleukin (IL)-1β, KC (murine IL-8 homolog), IL-10, transforming growth factor (TGF)-β, and vascular endothelial growth factor (VEGF) (PeproTech, Rocky Hill, NJ, USA; R&D, Minneapolis, MN, USA) were quantified in lung homogenate with ELISA kits, in accordance with the manufacturers' instructions.
Moreover, levels of IL-10, TGF-β, RvD1, and PGE 2 were quantified in the supernatants of nonpreconditioned and EPA-preconditioned AD-MSCs. For this purpose, in vitro experiments were performed: 10 5 ADMSCs were added to a 12-well plate and cultured for 24 h under normal conditions (DMEM-high glucose medium supplemented with 10% FBS, 1000 U/mL penicillin/streptomycin, and 2 mM L-glutamine; Invitrogen Life Technologies, Grand Island, NY, USA). The next day, AD-MSCs received conditioned medium (FBS-free) and were stimulated or not with EPA for 6 h. After stimulation, the supernatants were collected and levels of IL-10, TGF-β (assessed by ELISA, Biolegend, San Diego, CA, USA), RvD1, and PGE 2 (assessed by EIA, Cayman Chemical, Ann Arbor, MI, USA) were analyzed, as per manufacturer instructions. Results are expressed as picogram per milliliter.
Biodistribution of AD-MSCs labeled with technetium-99m
Nonpreconditioned and EPA-preconditioned AD-MSCs were labeled with 99m TcO 4 − as previously described [25] . All the procedures for cell preparation and labeling were carried out in a laminar flow hood. Briefly, 0.5 mL of fresh and sterile SnCl 2 solution was added to the cell suspension in saline solution, and the mixture was incubated at room temperature for 10 min. Then, 45 MBq of 99m TcO 4 − was added, and the incubation continued for another 10 min. After centrifugation (500×g for 5 min), the supernatant was removed, and the cells were washed once more with NaCl 0.9% solution. The pellet was suspended in NaCl 0.9%, and the viability of the labeled cells was assessed by the trypan blue exclusion test. Labeling efficiency (percentage) was calculated as: 
Statistical analysis
Sample size calculation was based on our previous experience using this CLP model [20] . The KolmogorovSmirnov test with Lilliefors' corrections was used to test for normality of data, while the Levene median test was used to evaluate the homogeneity of variances. Parametric data were assessed using one-way analysis of variance (ANOVA) followed by Tukey's test. Survival curves were derived by the Kaplan-Meier method and compared by the log-rank test. Nonparametric data were analyzed using the Kruskal-Wallis test followed by Dunn's test. Parametric data were expressed as mean ± standard deviation (SD), while nonparametric data were expressed as median (interquartile range). All tests were performed in GraphPad Prism v6.01 (GraphPad Software, La Jolla, California, USA). A two-sided P value < 0.05 was considered significant.
Results
EPA preconditioning did not affect AD-MSC morphology, cell surface markers, survival, or expression of extracellular vesicles, but increased secretion of biomarkers by AD-MSCs
To evaluate whether EPA has any effect on AD-MSC, an in vitro analysis of AD-MSC morphology, cell surface markers, expression of extracellular vesicles, and biomarkers secreted by AD-MSCs was performed.
Nonpreconditioned and EPA-preconditioned ADMSCs similarly displayed the characteristic morphology, adherence to plastic culture flasks, and expression of MSC-specific surface markers (negative for CD31, CD45, and MHCII; positive for CD29, CD49e, and CD44) (Fig. 1) . Additionally, EPA preconditioning did not affect cell survival in comparison to nonpreconditioned AD-MSCs (Fig. 2) . Both nonpreconditioned and EPA-preconditioned AD-MSCs also demonstrated formation of exosomes and microvesicles on MSC surfaces (Fig. 3) . EPA-stimulated AD-MSCs, compared with nonpreconditioned AD-MSCs, presented increased levels of RvD1, PGE2, IL-10, and TGF-β (Fig. 4) .
EPA-preconditioned AD-MSCs led to further improvements in clinical score and survival rate than nonpreconditioned AD-MSCs
On day 1, the CLP group demonstrated clinical features of moderate disease, while no abnormal features were observed in C mice (Fig. 5a ). On day 2, the CLP-SAL group demonstrated clinical features of severe disease, while C mice continued to show no abnormal features. Compared to CLP-SAL, clinical score was significantly improved to levels consistent with moderate and mild disease in mice receiving nonpreconditioned and EPApreconditioned AD-MSCs, respectively.
On day 7, the survival rate of C animals was 100%, versus 43% in the CLP-SAL group (Fig. 5b) . Administration of nonpreconditioned AD-MSCs improved survival in CLP animals to 71%, while administration of EPApreconditioned AD-MSCs improved survival to 86%.
EPA-preconditioned AD-MSCs led to a further improvement in lung mechanics than nonpreconditioned AD-MSCs
The CLP-SAL group demonstrated higher Est,L compared to C mice (63%) (Fig. 6 ). Nonpreconditioned and EPA-preconditioned AD-MSCs reduced Est,L; however, EPA-preconditioned AD-MSCs were more effective than nonpreconditioned AD-MSCs at reducing Est,L to Ccomparable levels.
EPA-preconditioned AD-MSCs were more effective at reducing alveolar collapse, interstitial edema, inflammation, and collagen fiber content than nonpreconditioned AD-MSCs Representative photomicrographs of lung parenchyma showed increased areas of alveolar collapse and alveolar septal inflammation (Fig. 7, upper panels) . AD-MSCs attenuated alveolar collapse and alveolar septal inflammation, whereas administration of EPA-preconditioned AD-MSCs led to a further reduction in these parameters. DAD score, which represents the severity of alveolar collapse, interstitial edema, and alveolar septal inflammation, was increased in CLP-SAL compared to the C group, due to statistically significant increases in these three parameters (Fig. 7, lower  panels) . Nonpreconditioned AD-MSCs led to a significant reduction in alveolar collapse, interstitial edema, and alveolar septal inflammation, resulting in a decrease in DAD score; however, EPA-preconditioned AD-MSCs were even more effective at reducing these abnormalities to Ccomparable levels.
The CLP-SAL group demonstrated greater fraction area of mononuclear cells and neutrophils in lung tissue, and higher collagen fiber content compared to C mice (Table 1) . Nonpreconditioned and EPApreconditioned AD-MSCs reduced all these parameters, but EPA-preconditioned AD-MSCs were even Nonpreconditioned and EPA-preconditioned AD-MSCs reduced protein levels of inflammatory and fibrotic biomarkers in lung tissues, but EPA-preconditioned ADMSCs further reduced IL-1β and KC as well as increased VEGF levels Protein levels of pro-inflammatory (IL-1β, KC) and profibrotic (TGF-β) mediators were increased in lung tissue homogenates from CLP-SAL compared to C mice (Fig. 8) . Nonpreconditioned and EPA-preconditioned AD-MSCs reduced protein levels of IL-1β and KC, but only EPA-preconditioned AD-MSCs decreased these mediators to C-comparable levels. Nonpreconditioned and EPA-preconditioned AD-MSCs similarly reduced the level of TGF-β. Furthermore, C, CLP-SAL, and CLP-AD-MSC animals demonstrated similar VEGF protein levels; however, this parameter was significantly higher in CLP mice receiving EPA-preconditioned AD-MSCs. No differences were observed in IL-10 protein levels among experimental groups (data not shown).
EPA-preconditioned AD-MSCs were more effective than nonpreconditioned AD-MSCs to reduce total cells, monocytes, and neutrophils in the blood CLP-SAL animals exhibited an increase in total and differential cellularity in the blood compared to C mice (Fig. 9) . Both nonpreconditioned and EPA-preconditioned ADMSCs reduced all these cell counts, but EPApreconditioned AD-MSCs were even more effective and reduced total cells, monocytes, and neutrophils in the blood to C-comparable levels.
Only EPA-preconditioned AD-MSCs enhanced alveolar macrophage capacity for phagocytosis Alveolar macrophages from C and CLP-SAL groups exhibited similar phagocytosis capacity (Additional file 2: Figure S2 ). Co-culture of alveolar macrophages from EPA-preconditioned AD-MSCs were more effective at reducing abnormalities in distal organs than nonpreconditioned AD-MSCs
The CLP-SAL group demonstrated several morphological abnormalities in distal organs (the liver, kidney, heart, spleen, and small bowel) compared to C mice (Table 2 and Fig. 10 ). Both nonpreconditioned and EPA-preconditioned AD-MSCs reduced such abnormalities; however, therapeutic effects on the liver, kidney, heart, spleen, and small bowel were even more pronounced in mice receiving EPA-stimulated AD-MSCs.
EPA preconditioning did not affect AD-MSC distribution to tissues
One hour after administration, 99m
Tc-labeled AD-MSCs were present in several tissues, with higher prevalence in the lungs and kidneys. EPA preconditioning elicited no significant differences in AD-MSC biodistribution (Additional file 3: Figure S3) .
Discussion
In the model of CLP-induced sepsis used herein, EPApreconditioned AD-MSCs yielded greater therapeutic benefits in comparison to nonpreconditioned AD-MSCs by further reducing lung mechanics and histological abnormalities, inflammation, collagen fiber content, and morphological alterations in distal organs, while increasing VEGF levels in lung tissue. Additionally, lower disease severity scores and a higher survival rate were observed in CLP mice receiving EPA-preconditioned AD-MSCs.
CLP is one of the most relevant experimental models for polymicrobial sepsis research, since it resembles several features of human disease, including multiple organ dysfunction and high mortality [20, 26] . In this study, AD-MSCs were administered 24 h after CLP surgery to consider the time course of lung and distal organ injury, in contrast to previous studies in which MSCs were administered few hours after injury [7, 8, 27, 28] . Although the bone marrow is the most commonly used source of MSCs, the cells used herein were collected from adipose tissue, as it is estimated to contain a higher number of MSCs and, in the clinical setting, is readily accessible by liposuction [29, 30] . Furthermore, in a previous study of experimental acute respiratory distress syndrome, bone marrow-derived and adipose tissue-derived MSCs similarly improved lung function, reduced lung inflammation and remodeling, and mitigated liver and kidney injury [5] . In initial clinical trials, both bone marrow-derived and adipose tissue-derived MSCs appeared to be safe and feasible for the treatment of critically ill patients [12] [13] [14] , although further optimizations seem to be required to maximize therapeutic benefits.
The mechanisms by which MSCs exert their therapeutic actions remain incompletely elucidated, but paracrine secretion of trophic factors is considered a key underlying mechanism [5, 15] . Under regular conditions, MSCs can secrete or induce other cells to secrete several paracrine factors; however, recent studies have attempted to stimulate MSCs with certain agents prior to administration in order to enhance secretion of factors that could potentially result in further beneficial effects [6, [15] [16] [17] . In this context, EPA can modify the fatty acid composition of membranes in several cell types, as well as serve as a substrate for the cyclooxygenase and lipoxygenase enzymes, thus altering cell signaling and gene expression and reducing production of arachidonic acid-derived mediators [18, 19] . Although EPA preconditioning did not affect AD-MSC morphology, surface markers, in vitro survival, or in vivo biodistribution in the present study, we observed that EPA actively increased secretion of anti-inflammatory and pro-resolution mediators by AD-MSCs, including resolvin D 1 , PGE 2 , IL-10, and TGF-β, as in a previous study by our group that used bone marrow-derived MSCs in allergic asthma [17] .
The acute respiratory distress syndrome is a common and serious complication observed in septic patients [1] . Pathogen-and damage-associated molecular patterns trigger a complex pro-inflammatory response, leading to increased secretion of a wide range of pro-inflammatory mediators, including IL-1β and KC, which results in intense cellular infiltration into the lungs and loss of epithelial integrity [20, 31] . Nonpreconditioned AD-MSC administration led to reduction in protein levels of such mediators, significantly reducing neutrophil cell count in lung tissue, while improving lung mechanics. Notably, EPA-preconditioned AD-MSCs further improved some (but not all) of these endpoints, including alveolar neutrophilia in lung tissue, interstitial edema, and alveolar septal thickening. EPA preconditioning can mobilize the production of lipid-derived pro-resolution mediators, such as resolvins and protectins, that mitigate the production of pro-inflammatory mediators and prevent neutrophilic infiltration by inhibiting transendothelial migration [32, 33] .
Endothelial injury facilitates pulmonary edema formation and contributes to remodeling of the alveolarcapillary membrane [20, 31] . Both nonpreconditioned and EPA-preconditioned AD-MSCs were able to reduce TGF-β levels, interstitial edema, and collagen fiber content in the lung; however, EPA-preconditioned AD-MSCs were more effective at reducing alveolar collapse, interstitial edema, and lung fibrosis, while also increasing VEGF levels in lung tissue. The effects of cell-based therapy on VEGF levels in experimental lung injury have been conflicting; some studies have demonstrated increased expression [34, 35] , whereas others indicated a reduction [5, 36] . Such discrepancies can be attributed to differences in experimental model and severity (CLP vs. endotoxin), cell source and type (mononuclear cells vs. bone marrowderived or adipose tissue-derived MSCs), administration route (intratracheal vs. intravenous), and timing of therapy and analysis. In agreement with our current findings, another study indicated that MSCs increased VEGF levels in lung tissue, correlating with recovery of vascular endothelial cadherin, protection against endothelial apoptosis, and reduction of lung permeability in experimental lung injury. All these beneficial effects were significantly reduced by VEGF knockdown [37] . Additionally, EPA preconditioning can enhance MSC production of PGE 2 [17] , which can act as a negative regulator of collagen secretion by promoting more efficient wound healing and reepithelization [38] [39] [40] . PGE 2 also inhibits inflammation and neutrophil influx [39, 41] and stimulates macrophage polarization into the M2 profile rather than M1 [17, 28, 42] . In this line, our results indicate that only macrophages exposed to EPA-preconditioned AD-MSCs presented an increase in phagocytosis capacity, which can result in a more efficient bacterial clearance. Sepsis-induced systemic inflammation leads to morphological and functional abnormalities in multiple organs, resulting in clinical deterioration over time and, ultimately, death. MSC therapy has been demonstrated to protect the lungs and distal organs from damage in experimental models of sepsis by exerting antioxidative, anti-apoptotic, and anti-inflammatory effects [5, 28, 43, 44] . In this line, both nonpreconditioned and EPA-preconditioned ADMSCs reduced blood leukocyte counts and abnormalities in distal organs in the present study. Although no differences in AD-MSC distribution across tissues were observed, EPA-preconditioned AD-MSCs were greatly effective at reducing number of circulating inflammatory cells as well as abnormalities in the lungs and other organs, correlating with further improvements in the clinical score and survival of septic mice.
Conclusion
EPA-preconditioned AD-MSCs increased secretion of pro-resolution and anti-inflammatory mediators (RvD 1 , PGE 2 , IL-10, and TGF-β) by these cells. In CLP-induced sepsis, this was associated with further reductions in lung and distal organ damage, thus resulting in greater improvements in clinical score and higher survival rate, compared to therapy with nonpreconditioned ADMSCs. This may be a promising therapeutic approach to improve outcome in septic patients. Table 2 Semiquantitative analysis of distal organ damage Fig. 10 Representative photomicrographs of distal organs. Photomicrographs of slices from the liver (a-d), kidney (e-h), heart (i-l), spleen (m-p), and small bowel (q-t) stained with hematoxylin and eosin. a Normal liver architecture with intact hepatocytes (hep) surrounding the centrolobular vein (clv); b in the CLP-SAL group, liver damage was observed, with hepatocyte disarrangement (asterisk), hydropic degeneration of hepatocytes (single arrow), and an increased number of Kupffer cells (double arrows); c administration of nonpreconditioned AD-MSCs attenuated the liver architecture disarrangement (asterisk), hydropic degeneration of hepatocytes (single arrow), and number of Kupffer cells (double arrows); d administration of EPA-preconditioned AD-MSCs increased the number of regenerated hepatocytes (asterisk) and decreased the number of Kupffer cells (double arrows). e Normal kidney architecture with intact glomeruli (glo) and renal tubules (tub); f in the CLP-SAL group, kidney damage was characterized by acute tubular necrosis (single arrow) with glomerular damage (double arrows); g administration of nonpreconditioned AD-MSCs attenuated both the acute tubular necrosis (single arrow) and glomerular damage (double arrows); h administration of EPA-preconditioned AD-MSCs increased the number of regenerated renal tubules (asterisk) and further attenuated acute tubular necrosis (single arrow) and glomerular damage (double arrows). i Normal heart architecture with intact muscle fibers (mf); j in the CLP-SAL group, heart damage was observed, with interstitial edema (asterisk) and microvacuolization of muscle fibers (arrows); k administration of nonpreconditioned AD-MSCs attenuated the interstitial edema and microvacuolization (arrows); l administration of EPA-preconditioned AD-MSCs decreased the interstitial edema and restored muscle fibers (arrows). m Normal spleen architecture with white pulp (wp) and red pulp (rp); n in the CLP-SAL group, spleen damage was observed, with activation of lymphocytes in white pulp, increased number of megakaryocytes in red pulp (single arrows), and augmented number of lymphoblasts and lymphocytes in white pulp (double arrows); o administration of nonpreconditioned ADMSCs maintained the activation of lymphocytes (double arrows) and decreased number of megakaryocytes in red pulp; p administration of EPApreconditioned AD-MSCs decreased the reactivity of lymphoid follicles (double arrows) and the number of megakaryocytes in red pulp. q Normal architecture of small bowel with preserved villi (vil), lamina propria (asterisk), and crypt of Lieberkuhn (cry); r in the CLP-SAL group, small-bowel damage was observed, characterized by villi enlargement (single arrow), edema of lamina propria (asterisk), and increased number of enteroblasts in crypts of Lieberkuhn (double arrows); s administration of nonpreconditioned MSCs mitigated the villi enlargement (single arrow) and reduced number of enteroblasts in crypts of Lieberkuhn (double arrows); t administration of EPA-preconditioned AD-MSCs restored normal small bowel architecture mitigated edema of the lamina propria (asterisk) and led to a further reduction in the number of enteroblasts in crypts of Lieberkuhn (double arrows). Sepsis was induced by cecal ligation and puncture (CLP), while sham-operated animals were used as control (C). Twenty-four hours after surgery, the CLP group received saline (0.05 mL, SAL), adipose tissue-derived mesenchymal stromal cells (AD-MSC; 10 5 cells) (nonpreconditioned), or preconditioned with eicosapentaenoic acid (AD-MSC-EPA; 10 5 cells)
